CliffBio
small molecule

SEGLUROMET

ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE

Loss of exclusivityDecember 2031latest FDA-listed patent expiry
CompanyMERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC

Drug detail

Brand nameSEGLUROMET
Active ingredientERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE
Strength2.5MG;500MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2017
Marketing statusRX

Listed patents

PatentExpiresType
8080580December 2031substance, product
9439902October 2030use U-2214
9308204October 2030product

More from MERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

SEGLUROMET patent cliff — loss of exclusivity December 2031 | CliffBio